Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celcuity Inc (NQ: CELC )

10.26 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.26
Bid (Size) 4.110 (2)
Ask (Size) 11.63 (2)
Prev. Close 10.26
Today's Range 10.26 - 10.26
52wk Range 4.810 - 14.40
Shares Outstanding 15,459,739
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE

Performance

YTD
-19.97%
-19.97%
1 Month
-10.12%
-10.12%
3 Month
-6.64%
-6.64%
6 Month
+20.85%
+20.85%
1 Year
+25.27%
+25.27%

More News

Read More
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
Via ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
Via ACCESSWIRE
Celcuity: Q2 Earnings Insights
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Celcuity Closes $100 Million Private Placement
Via ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Via ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
Via ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Earnings Outlook For Celcuity
Via Benzinga
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
From Celcuity Inc.
Via AccessWire
Exposures Product Safety
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
From Celcuity Inc.
Via AccessWire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.